Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690989 | 0.90 | EGFR (0.65) | EGFRERBB2 | |
| SCHEMBL13857428 | 0.84 | EGFR (0.67) | EGFRERBB2 | |
| SCHEMBL691634 | 0.75 | TNNI3K (0.59) | EGFRSRCLRRK2CCNT1CDK9 | |
| SCHEMBL691623 | 0.74 | EGFR (0.82) | EGFRERBB2 | |
| SCHEMBL2203654 | 0.73 | EGFR (0.47) | EGFRERBB2SRCLRRK2 | |
| SCHEMBL14772971 | 0.73 | EGFR (0.45) | EGFRSRCLRRK2 | |
| SCHEMBL12262286 | 0.73 | ERBB2 (0.51) | EGFRERBB2SRCLRRK2 | |
| SCHEMBL24968811 | 0.71 | EGFR (0.59) | EGFRERBB2LRRK2 | |
| SCHEMBL13814707 | 0.71 | EGFR (0.62) | EGFRERBB2 | |
| SCHEMBL12431497 | 0.71 | THRB (0.57) | EGFRSRCLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RES INC (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RES INC (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ERBB2 918/4885SRC 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.